Background Hypothyroidism has been suggested as a predisposing and prognostic factor in patients with spontaneous coronary ...

For patients across all indications treated within the RP2D range early, promising progression-free survival (PFS) and ...

Biohaven Ltd. narrows focus to three late-stage clinical programs and implements cost-cutting to address heavy R&D spending.

To keep up with COPD research and care developments, the 2026 Global Initiative for Chronic Obstructive Lung Disease report ...

Beyond a cancer cell’s genetic blueprint, the expression levels of certain proteins on its surface is emerging as a collection of critical, actionable biomarkers. Instead of looking for a mutated gene ...

Cholesteryl ester transfer protein inhibition has previously demonstrated significant efficacy in reducing atherogenic lipids and may benefit high-risk patients who are unable to achieve their LDL ...

Presented detailed efficacy and safety results from the PIK3CA wild-type ("WT") cohort of the Phase 3 VIKTORIA-1 clinical trial at a late breaking oral presentation at the 2025 European Society for Me ...

Company achieved FDA alignment on Phase 3 Oz-V trial for the treatment of 2L+ OPSCC, which will evaluate dual primary endpoints with potential of ...

Artiva Biotherapeutics, Inc. (Nasdaq: ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop ...

PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; interim and final analyses will occur ...

Late-breaking results from clinical trials, debates about lifestyle choices and cardiovascular risk, and improving clinical care with generative AI are among the topics being presented by UC San ...

Q3 2025 Earnings Call Transcript November 13, 2025 Operator: Greetings, and welcome to the HeartBeam Third Quarter 2025 ...